B-lymphoblastic leukemia/lymphoma, BCR-ABL1–like

This phase 3 trial tests imatinib, a targeted cancer drug, with two different chemotherapy backbones in children and adolescents with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). The goal is to see if a less intense chemo regimen works as well as the s…

This study tested a combination of the immunotherapy drug blinatumomab with either standard chemotherapy or dasatinib and prednisone in adults aged 65 and older with acute lymphoblastic leukemia (ALL). The goal was to see if the combination could improve survival and control the …

This phase I trial tests the safety of adding ruxolitinib to a standard combination of dasatinib and dexamethasone for adults aged 40 and older with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). The study starts with a low dose of ruxoli…

This early-phase trial is testing whether adding the drug venetoclax to a chemotherapy regimen originally designed for children can be safe and effective for adults aged 18-54 with a specific, aggressive form of B-cell acute lymphoblastic leukemia (Ph-like ALL). The study will en…

This Phase 2 trial tests whether adding the targeted drug ponatinib to standard chemotherapy can improve outcomes for adults with a specific, high-risk type of acute lymphoblastic leukemia called BCR/ABL1-like ALL. The study enrolls 32 patients aged 18-65 who have not yet been tr…

This study tests whether adding levocarnitine, a natural nutrient, to standard chemotherapy can prevent severe liver damage in teens and young adults (ages 15-39) with leukemia or lymphoma. About 440 participants will receive either chemotherapy alone or chemotherapy plus levocar…